Schubert & CO Biogen Inc. Transaction History

Schubert & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	SELL	$256.56 - $292.34 $769 - $877	-3 Reduced 6.25%	45 $12,000
Q4 2022 Jan 31, 2023	BUY	$252.44 - $306.72 $3,029 - $3,680	12 Added 33.33%	48 $13,000
Q3 2022 Oct 21, 2022	BUY	$194.69 - $268.46 $778 - $1,073	4 Added 12.5%	36 $10,000
Q2 2022 Aug 01, 2022	BUY	$187.54 - $223.02 $3,000 - $3,568	16 Added 100.0%	32 $7,000
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $1,162 - $1,464	6 Added 60.0%	16 $3,000
Q4 2021 Jan 28, 2022	BUY	$223.92 - $287.77 $2,239 - $2,877	10 New	10 $2,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Schubert & CO, based on Form 13F filings with the SEC.

Stay updated on Schubert & CO with notifications on news.